Price Chart

Executive Summary

JP Morgan double upgraded AXP from Neutral to Overweight on July 13, 2026, raising the price target to $400 from $328, implying 14.1% upside from the current $350.58. The firm's 56% accuracy on 9 AXP calls and 9.5% average return rank it above average among covering analysts. Consensus is mixed: 18 Buy/Strong Buy (42%), 17 Hold (40%), 1 Sell (2%) from 36 analysts. The mean target is $371.38, median $370, with a high of $450 and low of $312. JP Morgan's new $400 target sits above the mean and median, signaling conviction. Momentum is positive with 2 upgrades and 0 downgrades in the past 30 days, though EPS revisions are slightly negative (3 up vs 5 down for the current quarter). A single insider sale of $2.4M on June 15 is a weak bearish signal, while a congressional buy in May is a minor bullish tick. Institutional buying is strong, with several funds adding or doubling positions. Short interest at 65.3% of TRF volume is elevated, suggesting potential squeeze fuel. The next earnings report is due July 16, just 3 days after this upgrade, adding timing significance. Bottom line: a high-conviction double upgrade from a 56%-accurate firm with a 9.5% average return, above-consensus PT, and strong institutional support — bullish for AXP near-term.

Impact Score

Consensus & Targets

Consensus is mixed: 5 Strong Buy, 13 Buy (42% bullish), 17 Hold (40% neutral), 0 Sell, 1 Strong Sell (2% bearish) from 36 analysts. The consensus leans slightly bullish but with a large neutral camp, making JP Morgan's double upgrade a notable contrarian push toward the bullish side.

Current price: $350.58. Mean target: $371.38, median: $370. High: $450, low: $312. Implied upside to mean: 5.9%. JP Morgan's $400 target is 7.7% above the mean and 8.1% above the median, placing it in the top quartile of analyst targets. The prior PT of $328 was below the mean; the new PT signals a significant re-rating.

Recent Analyst Activity

30-day analyst activity: 2 upgrades (JP Morgan double upgrade, Piper Sandler initiate Overweight), 0 downgrades. EPS revisions are mixed: current quarter has 3 upward revisions vs 5 downward in the past 30 days, but the current EPS estimate of $4.40498 is slightly above the 30-day-ago estimate of $4.38435. Full-year 0y estimates show 4 up vs 4 down revisions, with the current estimate of $17.74912 above the 30-day-ago $17.68787. Overall, estimates are stabilizing with a slight upward bias.

Firm Track Record — JP Morgan

JP Morgan accuracy: 55% on 5701 calls | avg return: 5.6%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

JP Morgan has 56% accuracy on 9 AXP calls with a 9.5% average return, ranking above average among covering firms. The best-performing firms on AXP are TD Cowen, Goldman Sachs, and Deutsche Bank (all 100% on 2 calls each). The worst are UBS and Keefe, Bruyette & Woods (50% on 2 and 6 calls, respectively). JP Morgan's track record is solid but not elite, making this double upgrade a meaningful but not top-tier signal.

Earnings Estimates

Next earnings: Jul 16, 2026

Cross-Platform Signals

Insider activity: one SELL by McNeal Glenda G on June 15 for $2.4M — a weak bearish signal per academic literature (insider sales are often liquidity-driven). Congressional activity: one buy by Rep. Rick Allen (R) on May 8 for $1K-$15K — a minor bullish tick. Institutional changes are strongly bullish: 5 funds added or doubled positions, including ABN AMRO (+1,384%), Empowered Funds (+189%), and Integrated Wealth Concepts (+79%). Short interest is elevated at 65.3% of TRF volume, suggesting potential squeeze risk. The analyst signal converges with institutional buying and diverges from the insider sale (which is weak). Overall, cross-platform signals are bullish.

Investment Themes

Documents Analyzed

Report based on filing metadata.

US Market Status